COMMUNIQUÉS West-GlobeNewswire

Firefly Neuroscience’s Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial’s AI-Native Operating System for Brain Medicine
17/09/2026
– This integration of Firefly’s FDA 510(k)-cleared, AI-powered EEG/ERP technology follows Radial’s August 2026 acquisition of the management services organization supporting Mindful Health Solutions, forming the country [...]
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
17/09/2026
Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10 -6 sensitivity now preferred [...]
Catheter Precision Expands LockeT Commercialization Across Latin America Following Successful Launch in Brazil
17/09/2026
LockeT Has Expanded to Six Hospitals in Brazil Since Its August Launch Company Engages Experienced Cardiology Group to Support Expansion Across Argentina, Chile, Colombia and Additional Latin American Markets FORT MILL [...]
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
17/09/2026
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for [...]
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
17/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for [...]
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
17/09/2026
Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care from a healthcare [...]
Matisse Pharmaceuticals closed Series A financing round to advance isupartob sodium through phase 2 clinical development
17/09/2026
Geleen, September 17, 2026 Matisse Pharmaceuticals B.V., a clinical stage company developing isupartob sodium for the treatment of sepsis, today announced the successful completion of its Series A financing round. The € [...]
Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board
17/09/2026
Appointment supports Aerska's progression of its antibody-oligo conjugate platform and growing pipeline of RNA therapeutics for CNS disease Laura brings decades of leadership in developing complex genetic medicines from [...]
First Insight Corporation Launches The Focal Point Podcast
17/09/2026
Monthly conversations on where AI is changing healthcare, where it falls short, and what responsible innovation looks like PORTLAND, Ore., Sept. 17, 2026 (GLOBE NEWSWIRE) -- First Insight Corporation launched The Focal [...]
Recludix Pharma to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
17/09/2026
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy [...]
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
17/09/2026
Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size Pharma KANSAS CITY, Kan., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a [...]
SNIPR enrolls first patient in Phase 2 portion of SNIPR001 trial, expanding study to 66 patients
17/09/2026
COPENHAGEN, Denmark, Sept. 17, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced that the first patient has been enrolled in Part 2 of the Phase 1b/2a clinical trial of SNIPR001 (NCT06938867), the Company's lead CRISPR- [...]
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
17/09/2026
Yale physician-scientist and biotech entrepreneur Dr. Ranjit Bindra brings deep expertise in DNA repair, synthetic lethality and brain tumor therapeutics VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) -- [...]
Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
17/09/2026
Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular [...]
Boehringer Ingelheim launches PED Essentials, an online learning resource that gives patients a stronger voice
17/09/2026
Patient experience data (PED) are direct insights that patients provide on their symptoms, quality of life, treatment preferences and unmet needs. PED Essentials is an online learning hub, co-created with patients and [...]
Tarja Stenvall Appointed Chief Executive Officer of Bavarian Nordic
17/09/2026
COPENHAGEN, Denmark, September 17, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Tarja Stenvall has been appointed President and Chief Executive Officer, effective October 15, 2026, succeeding Paul Chaplin [...]
Le Groupe RAMSAY SANTE dévoile "Connecting Care 2030"
17/09/2026
COMMUNIQUÉ DE PRESSE Paris, le 17 septembre 2026 Le groupe Ramsay Santé dévoile « Connecting Care 2030 », pour accélérer sa croissance rentable et créer de la valeur durable pour l’ensemble de ses parties prenantes « [...]
RAMSAY SANTE Group unveils "Connecting Care 2030"
17/09/2026
PRESS RELEASE Paris, 17 September 2026 Ramsay Santé Group unveils “Connecting Care 2030” to drive next phase of profitable growth and create long term value for all stakeholders “Connecting Care 2030”, Ramsay Santé [...]
MEDVi QUAD Formula Update Confirmed for 2026: Apomorphine Replaces PT-141 in Current 4-in-1 Combination
17/09/2026
Sildenafil, Tadalafil, Apomorphine, and L-Citrulline Confirmed as MEDVi's Current QUAD Formulation for Compounded ED Treatment Newark, DE, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Compounded medications are not FDA-approved [...]

Pages